Pan American Silver Corp. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Pan American Silver Corp. Common Stock trades at $42.69 (market cap $18.39B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Pan American Silver Corp. Common Stock is the larger of the two by market cap, and Pan American Silver Corp. Common Stock pays a 1.65% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pan American Silver Corp. Common Stock for 2 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| PAAS | PCVX | |
|---|---|---|
Market Cap | $18.39B | $10.51B |
Volume | 3,168,808 | 2,644,694 |
Sector | Basic Materials | Health |
52-Week High | $68.70 | $73.82 |
52-Week Low | $33.20 | $40.32 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $17.52B | $9.14B |
Dividend Yield | 1.65% | — |
Signals from Pluang's Aura AI — not financial advice
Pan American Silver (PAAS) trades at $44.53, down 2.58% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $978M net income and a 32.03% net margin, and analysts project 2026 revenue growth to $4.3B. Recent news highlights growth from the Timmins and La Colorada projects and a director retirement effective October 31, 2026.
The outlook is positive with a consensus price target of $62.50, implying 40% upside, supported by solid cash flow and reserve growth. Risks include silver price volatility and potential cost pressures. Analyst sentiment is bullish with 52% buy ratings, but technical indicators suggest near-term caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →